Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

9904	Companies
199560	Keywords
130428	Articles
106065	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 08/01/2025 at 13:00, 6 months 20 days ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Moderna reports Q2 revenue of $0.1B, net loss of $(0.8)B, updates 2025 revenue to $1.5-$2.2B due to shipment timing, improves operating expenses by $400M, reiterates $6B year-end cash balance. FDA approvals for flu vaccine

Revenue Moderna Q2 2025 FDA Approvals
BRIEF

published on 08/01/2025 at 12:05, 6 months 20 days ago

UK Court Confirms Validity of Moderna's EP'949 Patent

Patent MRNA Technology Moderna Pfizer/BioNTech UK Court
PRESS RELEASE

published on 08/01/2025 at 12:00, 6 months 20 days ago

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Moderna's EP'949 patent validity upheld by UK Court of Appeal in Pfizer/BioNTech case. Recent legal developments in Europe further strengthen Moderna's intellectual property portfolio

MRNA Technology Moderna Pfizer/BioNTech EP'949 Patent UK Court Of Appeal
BRIEF

published on 07/30/2025 at 22:10, 6 months 22 days ago

Moderna Gains European Approval for New COVID-19 Vaccine

COVID-19 Vaccine European Commission Moderna SARS-CoV-2 SPIKEVAX®
PRESS RELEASE

published on 07/30/2025 at 22:05, 6 months 22 days ago

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna receives marketing authorization from the European Commission for updated COVID-19 vaccine Spikevax® targeting SARS-CoV-2 variant LP.8.1

COVID-19 Vaccine European Commission Moderna Spikevax LP.8.1
BRIEF

published on 07/28/2025 at 13:05, 6 months 24 days ago

Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025

MRNA Therapeutics Moderna Melanoma Bladder Cancer ESMO Congress 2025
PRESS RELEASE

published on 07/28/2025 at 13:00, 6 months 24 days ago

Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene

Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF

published on 07/25/2025 at 14:50, 6 months 27 days ago

EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE

published on 07/25/2025 at 14:45, 6 months 27 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season

COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF

published on 06/30/2025 at 13:05, 7 months 21 days ago

Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010

Accesswire

Published on 02/21/2026 at 00:45, 1 day 1 hour ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 1 day 1 hour ago

Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:15, 1 day 2 hours ago

DigiPower X Announces Closing of Settlement
Published on 02/20/2026 at 23:00, 1 day 2 hours ago

Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 1 day 3 hours ago

Organto Foods Completes Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 02/21/2026 at 12:00, 13 hours 51 minutes ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Published on 02/20/2026 at 18:36, 1 day 7 hours ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 1 day 7 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 1 day 7 hours ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 1 day 7 hours ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

Les Echos

Published on 02/20/2026 at 19:29, 1 day 6 hours ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 18:00, 1 day 7 hours ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 09:28, 1 day 16 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
Published on 02/20/2026 at 07:30, 1 day 18 hours ago

Announcement of share buyback in the context of a share purchase plan
Published on 02/20/2026 at 07:30, 1 day 18 hours ago

EURAZEO COMPLETES THE SALE OF EX NIHILO TO L CATTERTON

View all LES ECHOS COMFI WIRE